Fabrice Andre

发表

Prediction of the outcome of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responses

René Natowicz, Euler Guimarães Horta, Roman Rouzier, 2008, BMC Bioinformatics.

An asterisk indicates reviewers who have evaluated three or more manuscripts in 2012.

David Ball, Ash A. Alizadeh, David A. August, 2013 .

Precision medicine for metastatic breast cancer.

Fabrice Andre, F. André, E. Deluche, 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Evaluation of biological pathways involved in chemotherapy response in breast cancer

Jing Wang, Lajos Pusztai, Christos Sotiriou, 2008, Breast Cancer Research.

Reproducibility of research and preclinical validation: problems and solutions

Christos Hatzis, Lajos Pusztai, Fabrice Andre, 2013, Nature Reviews Clinical Oncology.

Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array

Philippe Dessen, Stefan Michiels, Lajos Pusztai, 2009, Clinical Cancer Research.

Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives.

Fabrice Andre, F. André, M. Dieci, 2013, Cancer discovery.

DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: current data and issues on study design.

Lajos Pusztai, Fabrice Andre, G. Hortobagyi, 2006, Biochimica et biophysica acta.

Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study.

Lajos Pusztai, Christos Sotiriou, Kenneth R Hess, 2007, The Lancet. Oncology.

Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.

Yuan Qi, Lajos Pusztai, Charles Coutant, 2011, Journal of the National Cancer Institute.

Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis.

Stefan Michiels, Benjamin Haibe-Kains, Christine Desmedt, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Implications of personalized medicine—perspective from a cancer center

Fabrice Andre, F. André, V. Lazar, 2011, Nature Reviews Clinical Oncology.

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

Carsten Denkert, Peter A Fasching, Andreas Schneeweiss, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.

Heikki Joensuu, Carsten Denkert, Damien Drubay, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer.

Roman Rouzier, Lajos Pusztai, Kenneth R Hess, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular Pathways Molecular Pathways : Involvement of ImmunePathways in the Therapeutic Response and Outcome in Breast Cancer

Carsten Denkert, Giuseppe Curigliano, Christos Sotiriou, 2012 .

Genomic index of sensitivity to endocrine therapy for breast cancer.

Peter Regitnig, Christos Hatzis, Lajos Pusztai, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.

Fabrice Andre, Vered Stearns, R. Bast, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.

Qingyuan Zhang, Kunwei Shen, Masakazu Toi, 2015, The Lancet. Oncology.

Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.

Yuan Qi, Christos Hatzis, Lajos Pusztai, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-generation genomic tests for breast cancer treatment.

Fabrice Andre, Suzette Delaloge, 2010, The Lancet. Oncology.

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

Manuel Hidalgo, Martin Schuler, Fabrice Andre, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.

Ian Krop, Fabrice Andre, Vered Stearns, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.